edetic acid has been researched along with capromab pendetide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, JC; Gerstbrein, J; Kahn, D; Maguire, RT; Miller, SJ; Williams, RD | 1 |
1 trial(s) available for edetic acid and capromab pendetide
| Article | Year |
|---|---|
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Edetic Acid; Gonadotropin-Releasing Hormone; Humans; Immunoconjugates; Leukopenia; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Radioimmunodetection; Salvage Therapy; Soft Tissue Neoplasms; Thrombocytopenia; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Yttrium Radioisotopes | 1999 |